抗生素耐药性
抗生素
微生物学
青霉素
利奈唑啉
SCCmec公司
达托霉素
金黄色葡萄球菌
抗菌剂
耐甲氧西林金黄色葡萄球菌
医学
万古霉素
生物
病毒学
细菌
遗传学
作者
Bandar Ali Alghamdi,Intisar Al-Johani,Jawhra M. Al-Shamrani,Hussein Musamed Alshamrani,Bandar G Al-Otaibi,Kholod Almazmomi,Nik Yusnoraini Yusof
标识
DOI:10.1016/j.sjbs.2023.103604
摘要
In the medical community, antibiotics are revered as a miracle because they stop diseases brought on by pathogenic bacteria. Antibiotics have become the cornerstone of contemporary medical advancements ever since penicillin was discovered. Antibiotic resistance developed among germs quickly, placing a strain in the medical field. Methicillin-resistant Staphylococcus aureus (MRSA), Since 1961, has emerged as the major general antimicrobial resistant bacteria (AMR) worldwide. MRSA can easily transmit across the hospital system and has mostly gained resistance to medications called beta-lactamases. This enzyme destroys the cell wall of beta-lactam antibiotics resulting in resistance against that respective antibiotic. Daptomycin, linezolid and vancomycin were previously used to treat MRSA infections. However, due to mutations and Single nucleotide polymorphisms (SNPs) in Open reading frames (ORFs) and SCCmec machinery of respective antibody, MRSA developed resistance against those antibiotics. The MRSA strains (USA300, CC398, CC130 etc.), when their pan-genomes were analyzed were found the genes involved in invoking resistance against the antibiotics as well as the epidemiology of that respective strain. PENC (penicillin plus potassium clavulanate) is the new antibiotic showing potential in treatment of MRSA though it is itself resistant against penicillin alone. In this review, our main focus is on mechanism of development of AMR in MRSA, how different ORFs are involved in evoking resistance in MRSA and what is the core-genome of different antimicrobial resistant MRSA.
科研通智能强力驱动
Strongly Powered by AbleSci AI